cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Kronos Bio Inc
3 own
2 watching
Current Price
$1.02
$-0.02
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
71.03M
52-Week High
52-Week High
2.29000
52-Week Low
52-Week Low
0.73100
Average Volume
Average Volume
0.08M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization71.03M
icon52-Week High2.29000
icon52-Week Low0.73100
iconAverage Volume0.08M
iconDividend Yield--
iconP/E Ratio--
What does the Kronos Bio Inc do?
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Read More
How much money does Kronos Bio Inc make?
News & Events about Kronos Bio Inc.
Globe Newswire
1 year ago
Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML Additional presentations highlight Kronos Bios collaboration with academic cooperative groups to better understand the predictive value of measurable ...
Globe Newswire
1 year ago
Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, ...
Globe Newswire
1 year ago
SAN MATEO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in ...
Globe Newswire
1 year ago
Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute myeloid leukemiaSAN MATEO, Calif. and CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to ...
Ticker Report
2years ago
Kronos Bio, Inc. (NASDAQ:KRON Get Rating) CEO Norbert W. Bischofberger acquired 90,931 shares of the companys stock in a transaction dated Tuesday, May 17th. The shares were purchased at an average price of $3.83 per share, for a total transaction of $348,265.73. Following the ...
Frequently Asked Questions
Frequently Asked Questions
What is Kronos Bio Inc share price today?
plus_minus_icon
Can Indians buy Kronos Bio Inc shares?
plus_minus_icon
How can I buy Kronos Bio Inc shares from India?
plus_minus_icon
Can Fractional shares of Kronos Bio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Kronos Bio Inc stocks?
plus_minus_icon
What is today’s traded volume of Kronos Bio Inc?
plus_minus_icon
What is today’s market capitalisation of Kronos Bio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Kronos Bio Inc?
plus_minus_icon
What percentage is Kronos Bio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Kronos Bio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.02
$-0.02
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00